WHO-led COVAX vaccine scheme agrees new supply deal with Serum Institute

Serum Institute will supply 1.1 billion doses of Covid-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representational image of Covaxin
Reuters GENEVA/LONDON
1 min read Last Updated : Feb 03 2021 | 7:37 PM IST

India's Serum Institute will supply 1.1 billion doses of COVID-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme as part of a new long-term deal, head of the U.N. Children's Fund said on Wednesday.

UNICEF chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.

They would be produced by Serum under a technology transfer agreement, she said in a briefing.

The COVAX facility is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations and UNICEF.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSerum Institute of India

First Published: Feb 03 2021 | 7:29 PM IST

Next Story